TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune, Inc., a clinical-stage gene therapy company, today announced a license agreement with Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s) ...
We have previously shown that achieving factor VIII expression is possible in mice with hemophilia A with the use of mouse hematopoietic stem cells (HSCs) and in immunodeficient mice with the use of ...
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...
Lentiviral Vector CDMO Market Overview: The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results